Levodopa/Carbidopa/Entacapone G.L. Pharma

Levodopa, Carbidopa, Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone G.L. Pharma, is an Antiparkinson agent presented as an oral tablet for oral use. It treats Parkinson's disease and associated motor fluctuations in adult patients.

GNH USA supplies Levodopa/Carbidopa/Entacapone G.L. Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinsonian disorders and related motor complications.

- Parkinson's disease: improves overall motor function by increasing central dopamine levels. - Motor fluctuations in Parkinson's disease: reduces OFF periods and extends ON time. - Levodopa‑responsive Parkinsonian syndrome: provides more stable symptom control when combined with other antiparkinson agents.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Insomnia or vivid dreams - Dyskinesia (involuntary movements) - Dry mouth

Serious or Rare Side Effects: - Severe hypotension or syncope - Neuroleptic malignant syndrome - Allergic reactions such as rash, angioedema, or anaphylaxis - Hyperpyrexia or severe fever - Suicidal ideation or severe depression - Hallucinations or psychosis

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: watch for orthostatic drops, especially after dose changes. - Psychiatric assessment: evaluate for depression, hallucinations, or suicidal thoughts. - Renal/hepatic function: adjust dosing in patients with impairment. - Cardiac disease: use caution in patients with arrhythmias or ischemic heart disease. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal dyskinesia. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several drug classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Other COMT inhibitors: may cause excessive levodopa levels. - Antipsychotics that block dopamine receptors: reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect. - SSRIs or SNRIs: may increase risk of serotonin syndrome. - Iron or vitamin C supplements: can impair levodopa absorption if taken simultaneously.